CoChat
Sign Up
Cited by 86Nanoparticle-Based Drug DeliveryUltrasound and Hyperthermia ApplicationsLipid Membrane Structure and Behavior

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes

Open access
Al-Ahmady, Zahraa S., Hadjidemetriou, Marilena, Gubbins, James, Kostarelos, Kostas·2018·Journal of Controlled Release
DOI 10.1016/j.jconrel.2018.02.038
Open this paper in CoChat — free account

Abstract

Thermally triggered drug release from temperature-sensitive liposomes (TSL) holds great promise for cancer therapy. Different types of TSL have been designed recently for heat triggered drug release inside tumor blood vessels or after accumulation into the tumor interstitium. However, justification of drug release profiles is for far mainly based on in vitro release data. While these methods could be good enough to give early indication about the thermal sensitivity of TSL, they are still far from being optimum. This is because these methods do not take into consideration the actual adsorption of proteins onto the surface of TSL after their in vivo administration, also known as "protein corona" and the influence this could have on drug release. Therefore, in this study we compared thermal triggered drug release profile of two different types of doxorubicin encapsulated TSL; namely the lysolipid-containing TSL (LTSL) and traditional TSL (TTSL) after their in vivo recovery from the blood circulation of CD-1 mice. Ex vivo release profile at 42 °C was then tested either in the presence of full plasma or after removal of unbound plasma proteins (i.e. protein corona coated TSL). Our data showed that the influence of the environment on drug release profile was very much dependent on the type of TSL. LTSL release profile was consistently characterized by ultrafast drug release independent on the conditions tested. On the contrary, TTSL release profile changed significantly. Doxorubicin release from in vivo recovered TTSL was slow and incomplete in the presence of unbound plasma proteins, whereas very rapid drug release was detected from in vivo recovered and purified protein corona-coated TTSL in the absence of unbound proteins. Using mass spectrometry and quantification of protein adsorption, we confirmed that this discrepancy is due to the changes in protein adsorption onto TTSL when heated in the presence of unbound proteins leading to reduction in drug release. In summary this study showed that the formation of the in vivo corona on TSL will have a dramatic impact on their release profile and is dependent on both their lipid composition and the protein content of the environment in which drug release is triggered.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2018.02.038

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Plasma protein absorption on liposomal surface is inevitable even in the presence of PEG.

    “Unfortunately, plasma protein absorption on liposomal surface is inevitable even in the presence of PEG8,48,49.”

    From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [48]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. Yatvin, 1978, Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202, 1290, 10.1126/science.364652 · DOI
  2. Al-Ahmady, 2016, Chemical components for the design of temperature-responsive vesicles as cancer therapeutics, Chem. Rev., 116, 3883, 10.1021/acs.chemrev.5b00578 · DOI
  3. Manzoor, 2012, Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors, Cancer Res., 72, 5566, 10.1158/0008-5472.CAN-12-1683 · DOI
  4. Al-Ahmady, 2014, Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia, J. Control. Release, 196, 332, 10.1016/j.jconrel.2014.10.013 · DOI
  5. Al-Ahmady, 2012, Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo, ACS Nano, 6, 9335, 10.1021/nn302148p · DOI
  6. Al-Jamal, 2012, Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia, Biomaterials, 33, 4608, 10.1016/j.biomaterials.2012.03.018 · DOI
  7. Kong, 2000, Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release, Cancer Res., 60, 6950
  8. Al-Ahmady, 2015, Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: critical parameters and therapeutic efficacy, Int. J. Cancer, 137, 731, 10.1002/ijc.29430 · DOI
  9. Landon, 2011, Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer, Open Nanomed. J., 3, 38, 10.2174/1875933501103010038 · DOI
  10. Needham, 2013, Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and dspe-peg2000) on the thermal transition and release of doxorubicin, Faraday Discuss., 161, 515, 10.1039/C2FD20111A · DOI
  11. Li, 2013, Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy, J. Control. Release, 168, 142, 10.1016/j.jconrel.2013.03.011 · DOI
  12. Li, 2010, Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia, J. Control. Release, 143, 274, 10.1016/j.jconrel.2010.01.006 · DOI
  13. Hosokawa, 2003, Alteration in the temperature-dependent content release property of thermosensitive liposomes in plasma, Chem. Pharm. Bull., 51, 1227, 10.1248/cpb.51.1227 · DOI
  14. Gaber, 1995, Thermosensitive sterically stabilized liposomes - formulation and in-vitro studies on mechanism of doxorubicin release by bovine serum and human plasma, Pharm. Res., 12, 1407, 10.1023/A:1016206631006 · DOI
  15. Unezaki, 1994, Enhanced delivery and antitumor-activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene-glycol in combination with local hyperthermia, Pharm. Res., 11, 1180, 10.1023/A:1018949218380 · DOI
  16. Cedervall, 2007, Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles, Proc. Natl. Acad. Sci. U. S. A., 104, 2050, 10.1073/pnas.0608582104 · DOI · Paper page
  17. Hadjidemetriou, 2017, Nanomedicine: evolution of the nanoparticle corona, Nat. Nanotechnol., 12, 288, 10.1038/nnano.2017.61 · DOI
  18. Monopoli, 2013, Formation and characterization of the nanoparticle-protein corona, Methods Mol. Biol., 1025, 137, 10.1007/978-1-62703-462-3_11 · DOI
  19. Tenzer, 2013, Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology, Nat. Nanotechnol., 8, 772, 10.1038/nnano.2013.181 · DOI · Paper page
  20. Palchetti, 2016, The protein corona of circulating PEGylated liposomes, Biochim. Biophys. Acta, 189, 10.1016/j.bbamem.2015.11.012 · DOI
  21. Chonn, 1992, Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes, J. Biol. Chem., 267, 18759, 10.1016/S0021-9258(19)37026-7 · DOI
  22. Allen, 1991, Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta, 29, 10.1016/0005-2736(91)90246-5 · DOI
  23. Hadjidemetriou, 2016, Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles, Nano, 8, 6948
  24. Hadjidemetriou, 2015, In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles, ACS Nano, 9, 8142, 10.1021/acsnano.5b03300 · DOI · Paper page
  25. Tenzer, 2013, Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology, Nat. Nanotechnol., 8, 772, 10.1038/nnano.2013.181 · DOI · Paper page
  26. Pozzi, 2015, The biomolecular corona of nanoparticles in circulating biological media, Nano, 7, 13958
  27. Ge, 2011, Binding of blood proteins to carbon nanotubes reduces cytotoxicity, Proc. Natl. Acad. Sci. U. S. A., 108, 16968, 10.1073/pnas.1105270108 · DOI
  28. Salvati, 2013, Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface, Nat. Nanotechnol., 8, 137, 10.1038/nnano.2012.237 · DOI · Paper page
  29. Mirshafiee, 2013, Protein corona significantly reduces active targeting yield, Chem. Commun., 49, 2557, 10.1039/c3cc37307j · DOI
  30. Dai, 2014, Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting, Angew. Chem. Int. Ed. Eng., 53, 5093, 10.1002/anie.201309464 · DOI
  31. Pourjavadi, 2015, The effect of protein corona on doxorubicin release from the magnetic mesoporous silica nanoparticles with polyethylene glycol coating, J. Nanopart. Res., 17, 10.1007/s11051-015-3008-3 · DOI
  32. Garcia-Alvarez, 2018, In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape, Nano, 10, 1256
  33. Gaber, 1998, Effect of bovine serum on the phase transition temperature of cholesterol-containing liposomes, J. Microencapsul., 15, 207, 10.3109/02652049809006850 · DOI
  34. Mills, 2005, Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition, Biochim. Biophys. Acta Biomembr., 1716, 77, 10.1016/j.bbamem.2005.08.007 · DOI
  35. Needham, 2000, A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model, Cancer Res., 60, 1197
  36. Banno, 2010, The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo, J. Pharm. Sci., 99, 2295, 10.1002/jps.21988 · DOI
  37. Caracciolo, 2015, Lipid composition: a "key factor" for the rational manipulation of the liposome-protein corona by liposome design, RSC Adv., 5, 5967, 10.1039/C4RA13335H · DOI
  38. Mahmoudi, 2013, Temperature: the "ignored" factor at the NanoBio interface, ACS Nano, 7, 6555, 10.1021/nn305337c · DOI
  39. Hossann, 2012, Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes, J. Control. Release, 162, 400, 10.1016/j.jconrel.2012.06.032 · DOI
  40. Dewhirst, 2013, Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes, Surg. Oncol. Clin. N. Am., 22, 545, 10.1016/j.soc.2013.02.009 · DOI
  41. Hossann, 2007, In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes, Biochim. Biophys. Acta Biomembr., 1768, 2491, 10.1016/j.bbamem.2007.05.021 · DOI
  42. Park, 2013, Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU), J. Control. Release, 170, 373, 10.1016/j.jconrel.2013.06.003 · DOI
  43. Tagami, 2011, Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system, J. Control. Release, 154, 290, 10.1016/j.jconrel.2011.05.020 · DOI
  44. Lokerse, 2016, In depth study on thermosensitive liposomes: optimizing formulations for tumor specific therapy and in vitro to in vivo relations, Biomaterials, 82, 138, 10.1016/j.biomaterials.2015.12.023 · DOI
  45. de Smet, 2010, Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance, J. Control. Release, 143, 120, 10.1016/j.jconrel.2009.12.002 · DOI
  46. Kong, 1999, Hyperthermia and liposomes, Int. J. Hyperth., 15, 345, 10.1080/026567399285558 · DOI
  47. Peng, 2015, Enhanced biostability of nanoparticle-based drug delivery systems by albumin corona, Nanomedicine, 10, 205, 10.2217/nnm.14.86 · DOI
  48. Behzadi, 2014, Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface, Colloids Surf. B, 123, 143, 10.1016/j.colsurfb.2014.09.009 · DOI
  49. Cifuentes-Rius, 2013, Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release, ACS Nano, 7, 10066, 10.1021/nn404166q · DOI
  50. Needham, 2013, Chapter 12 - reverse engineering of the low temperature-sensitive liposome (ltsl) for treating cancer, 270

Cited by

Sorted by citations

Metadata

Authors
Al-Ahmady, Z. S., Hadjidemetriou, M., Gubbins, J., & Kostarelos, K.
Affiliations
University of Manchester (GB)
Corresponding author
Kostarelos, Kostas
ORCID
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2018-04
Volume
276
Pages
157-167
ISSN
0168-3659 (ISSN-L)
DOI
10.1016/j.jconrel.2018.02.038
OpenAlex
W2791841497
Cited by
86
References
1
Citations by year
2026: 1 · 2025: 12 · 2024: 7 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 23 · 2019: 10 · 2018: 2
FWCI
3.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by-nc-nd)
  • Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
Funders
  • Marie Curie Initial Training Network PathChooser (PITN-GA-2013-608373)
  • Wellcome Trust
  • University of Manchester
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Lipid Membrane Structure and Behavior
Keywords
protein corona, thermosensitive liposomes, doxorubicin, plasma protein adsorption, in vivo drug release, lipid composition, cancer therapy, tumor vasculature
MeSH terms
Protein Corona, Antibiotics, Antineoplastic, Blood Proteins, Doxorubicin, Liposomes, Temperature, Drug Liberation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review